Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users

Grebely J, Matthews GV, Hellard M, Shaw D, Shaw D, Petoumenos K, Yeung B, et al. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol. 2011;55(1):76-85.

Publication Type:

Journal Article

Authors:

Grebely, J.; Matthews, G.V.; Hellard, M.; Shaw, D.; I van Beek; Petoumenos, K.; Alavi, M.; Yeung, B.; Haber, P.S.; Lloyd, A.R.; Kaldor, J.M.; Dore, G.J.; ATAHC study group

Source:

J Hepatol, Volume 55, Issue 1, p.76-85 (2011)

Keywords:

adherence, administration & dosage, Adult, Antiviral Agents, Australia, clinical trial, Cohort Studies, complications, drug therapy, Drug Users, education, epidemiology, Female, HCV, hepatitis, Hepatitis C, hepatitis C virus, Hiv, Humans, Infection, interferon, Interferon Alfa-2a, Interferon-alpha, Logistic Models, Male, methods, Middle Aged, Multicenter Studies, New South Wales, Patient Compliance, Patients, peginterferon, pegylated, pegylated interferon, Polyethylene Glycols, Prospective Studies, Proteins, Recombinant Proteins, Research, Research Support, Ribavirin, Substance Abuse,Intravenous, SVR, therapeutic use, therapy, transmission, treatment, Treatment Outcome, Universities, virology, Wales, Young Adult

Notes:

PMC3117933

Cited On:

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/21145855

Export Citation:

RIS Format

Top